Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients
- First Online:
- 197 Downloads
The marketing of sumatriptan, a selective serotonin (5-HT) 1B/1D agonist, first of the class of triptans, has increased the therapeutic options for the treatment of migraine attacks. However, almost one third of patients in clinical trials fail to have headache relief after oral administration of sumatriptan.
To evaluate whether the interindividual differences in the clinical response following oral administration of sumatriptan are due to differences in its pharmacokinetics.
We compared the pharmacokinetics of sumatriptan after oral (100 mg) and subcutaneous (6 mg) administration in two age- and gender-matched groups: ten subjects (group A) with satisfactory response and ten (group B) with unsatisfactory response to oral sumatriptan. Patients were studied during headache-free intervals. Blood samples were taken serially from baseline to 360 min after oral administration and from baseline to 180 min after subcutaneous injection. Sumatriptan plasma concentrations were determined by high-performance liquid chromatography (HPLC) with an electrochemical detector.
Following oral dosing, patients of group A absorbed sumatriptan significantly faster and achieved early plasma levels significantly higher than patients of group B. The systemic exposure to sumatriptan during the first 2 h, which are the most important for rapid onset of action and for antimigraine efficacy, was significantly greater in group A than in group B (P < 0.001, Student’s t test for independent data). On the other hand, after subcutaneous injection of sumatriptan, the profile of the curves was similar in all patients, and there were no differences in pharmacokinetics between group A and group B.
The slow rate and low extent of absorption of the drug during the first 2 h after dosing observed in patients of group B could explain their unsatisfactory response to oral sumatriptan.
KeywordsSumatriptan Absorption Pharmacokinetics Variability Response
- 20.Headache Classification Subcommittee of the International Headache Society (2004) The international classification of headache disorders, 2nd edn. Cephalalgia 24(Suppl 1):S9–S160Google Scholar
- 24.Normann G, Streiner D (2000) Biostatistics. The bare essentials, 2nd edn. B.C. Decker Inc., Ontario, Canada, pp 1–162Google Scholar
- 27.Carpay J, Schoenen J, Ahmad F, Kinrade F, Boswell D (2004) Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clin Ther 26(2):214–223PubMedCrossRefGoogle Scholar
- 29.Sheftell FD, Dahlof CG, Brandes JL, Agosti R, Jones MW, Barrett PS (2005) Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Clin Ther 27(4):407–417PubMedCrossRefGoogle Scholar
- 36.Visser WH, de Vriend RH, Jaspers NH, Ferrari MD (1996) Sumatriptan non responders: a survey in 366 migraine patients. 36(8):471–475Google Scholar
- 42.Tfelt-Hansen P (2007) Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. A comment. J Headache Pain 8(5):273–276, Online DOI 10.1007/s10194-007-0411-x
- 44.Cutler NR, Hussey EK, Sramek JJ, Clements BD, Paulsgrove LA, Busch MA, Donn KH (1991) Oral sumatriptan in pharmacokinetics in the migranous state. Cephalalgia 11(Suppl 11):222–223Google Scholar